Thyrocare Technologies (THYROCARE) — Announcement

📢 Key Event
Thyrocare reported 26% YoY standalone revenue growth of INR 225.6 crores in Q1 FY27

🔄 What Changed
26% standalone revenue growth; 34% PAT growth; 900 franchisees added toward 1,500 annual target

🔮 What's Next
PAT guidance of ~INR 6 crores for full year; radiology divestment completion anticipated in 6 months

💡 Investor Takeaway
Shareholders should note PAT growth and strategic focus on specialty diagnostics and franchise expansion.

Thyrocare reported 26% YoY standalone revenue growth of INR 225.6 crores in Q1 FY27, driven by 26% pathology growth and expansion to 44 labs (including new Muzaffarpur, Kurnool, and Prayagraj locations). The company added 900 franchisees this quarter toward a 1,500 annual target, with plans to add 1,700 franchisees over three years through white space expansion and deeper market penetration. Specialty diagnostics (allergy and genomics) entered commercial operations, targeting 15-20% portfolio contribution within 3-5 years. Capex investments exceed INR 250 crores, while radiology divestment (INR 140 crores) is expected to improve return ratios within six months. PAT reached INR 1.72 crores with 34% YoY growth, supported by 32.2% EBITDA margins and 99% phlebotist arrival rates. Recognition as India's most trusted diagnostic brand and 100% NABL accreditation underscore quality leadership. The company clarified no API IPO plans exist, focusing instead on debt reduction before any corporate actions.

📄 View Original Announcement (PDF)

📊 Stock Analysis — THYROCARE ✨ Ask AI About This

About Thyrocare Technologies Limited (THYROCARE)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹9,402.69 Cr P/E: 34.6 ROE: 34.3% ROCE: 45.6% Div Yield: 1.18%

View full THYROCARE stock details →

📡 Get AI alerts when THYROCARE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track THYROCARE — Free

💡 Ask AI about this filing

"How will specialty diagnostics contribute to revenue mix by FY28?" "What is the expected debt reduction timeline to achieve debt-free status?" "When will the radiology divestment impact consolidated margins?"

Ask AI Free →

📊 More THYROCARE filings

See all THYROCARE filings →

🔥 Also filed on 27 July 2026

FAIRCHEMOR Fairchem Organics Limited Financial Results MPHASIS MphasiS Limited Insider Trading NTPC NTPC Limited Corporate Action CCL CCL Products (India) Limited Corporate Action ITI ITI Limited Announcement SHRIRAMFIN Shriram Finance Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when THYROCARE files new disclosures

Track THYROCARE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track THYROCARE — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd